This study aimed to characterize the expression of CD39 and CD73 on immune cells of RA patients before and after IL-6 blockage with tocilizumab (TCZ) treatment and to compare good responders (Rs) and non-good responders (NRs). This evidence concerns the gene ENTPD1 and rheumatoid arthritis.